Lilly Q1 revenue up 45% to $12.73B; EPS beat; reaffirms guidance

ELI LILLY & Co

2025-Q1 EPS reported $3.06 revenue$12,728,500,000

Revenue $12.73B (+45% YoY) driven by Mounjaro and Zepbound volume growth.
Reported EPS $3.06 (+23%); non-GAAP EPS $3.34 (+29%), including $1.72 IPR&D charges.
Revenue guidance reaffirmed at $58.0-$61.0 billion for full-year 2025.
Pipeline: positive Phase 3 for oral GLP-1 orforglipron in T2D; approvals in oncology/immunology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.